Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EBIT (2016 - 2025)

Historic EBIT for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to -$4.1 million.

  • Heron Therapeutics' EBIT rose 818.75% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 10616.1%. This contributed to the annual value of -$11.5 million for FY2024, which is 8957.83% up from last year.
  • Latest data reveals that Heron Therapeutics reported EBIT of -$4.1 million as of Q3 2025, which was up 818.75% from -$1.6 million recorded in Q2 2025.
  • Heron Therapeutics' EBIT's 5-year high stood at $4.2 million during Q4 2024, with a 5-year trough of -$62.9 million in Q1 2022.
  • Its 5-year average for EBIT is -$27.2 million, with a median of -$24.9 million in 2023.
  • As far as peak fluctuations go, Heron Therapeutics' EBIT tumbled by 2074.11% in 2022, and later surged by 16573.57% in 2025.
  • Over the past 5 years, Heron Therapeutics' EBIT (Quarter) stood at -$53.5 million in 2021, then surged by 61.98% to -$20.4 million in 2022, then surged by 49.79% to -$10.2 million in 2023, then skyrocketed by 140.83% to $4.2 million in 2024, then plummeted by 198.08% to -$4.1 million in 2025.
  • Its EBIT stands at -$4.1 million for Q3 2025, versus -$1.6 million for Q2 2025 and $3.2 million for Q1 2025.